Gennova biopharmaceutical

Human trials of mRNA vaccine against COVID-19's new variant Omicron is to begin from February. Notably, Pune-based Gennova Biopharmaceutical made mRNA vaccine and completed phase I and II trials and submitted a report to the Drugs Controller General of India (DCGI). Along with it, the company also submitted a data of Phase III trials and are waiting for their approval from the Vaccine Subject Expert Committee (SEC).